Asia
Reltecimod is a synthetic peptide antagonist of both superantigen exotoxins and the CD28 T-cell costimulatory receptor.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck and Eisai over their Lenvima and Keytruda combination for first-line treatment of unresectable hepatocellular carcinoma (HCC).
Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints.
Through the partnership, Takeda will have access to Twist’s “Library of Libraries,” a large phage display library created using precisely defined synthetic DNA sequences to discover unique antibodies to important therapeutic targets including GPCRs.
What if you could get one vaccine that protects you against a wide spectrum of viruses, even viruses we haven’t discovered yet?
Biopharma and life sciences companies provide updates on their pipelines and business plans.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Another pandemic may be building in China. This time, it’s a new strain of the H1N1 swine flu and it’s already jumped to humans.
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
PRESS RELEASES